Neurogene (NASDAQ:NGNE) & Foghorn Therapeutics (NASDAQ:FHTX) Critical Review

Neurogene (NASDAQ:NGNE) and Foghorn Therapeutics (NASDAQ:FHTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Earnings and Valuation

This table compares Neurogene and Foghorn Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	N/A	N/A	N/A	($5.03)	-5.37
Foghorn Therapeutics	N/A	N/A	N/A	($0.98)	-2.09

Neurogene is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.4% of Neurogene shares are held by institutional investors. Comparatively, 61.5% of Foghorn Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Neurogene and Foghorn Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1	0	5	2	3.00
Foghorn Therapeutics	1	6	4	0	2.27

Neurogene currently has a consensus target price of $80.29, suggesting a potential upside of 197.46%. Foghorn Therapeutics has a consensus target price of $6.14, suggesting a potential upside of 199.65%. Given Foghorn Therapeutics’ higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Neurogene.

Profitability

This table compares Neurogene and Foghorn Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	N/A	N/A
Foghorn Therapeutics	N/A	N/A	N/A

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

About Foghorn Therapeutics

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.